Ramon Vredeling
Value, foreign companies, commodities, special situations

Pharming's Ruconest Triggers Value Creation: Chinese Collaboration Joins U.S., EU Partners

(Editors' Note: This article covers a micro-cap stock. Please be aware of the risks associated with these stocks.)

In the early hours of July 1, 2013 Dutch biotech company Pharming Group NV (OTC:PHGUF) announced that the company has entered into a strategic collaboration with Shanghai Institute of Pharmaceutical Industry (SIPI), a Sinopharm Company (OTCPK:SHTDF), for the development, manufacture and commercialization of new products based on the Pharming technology platform. In addition, Pharming has also granted SIPI an exclusive license to commercialise Ruconest in China.

Ruconest for Heredity Angioedema (HAE) has been developed for the treatment of acute attacks of HAE. HAE is a rare genetic deficiency of C1 inhibitor activity resulting in recurrent attacks of...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details